Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about KYNB, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Roxadustat (FG-4592) | CKD Anemia in Dialysis Participants | Phase 4 · NCT04059913 | Completed |
| Therapeutic Corticosteroid | Duchenne Muscular Dystrophy | Phase 3 · NCT04632940 | Terminated |
| SEPO® | Chemotherapy Induced Anemia | Phase 3 · NCT05301517 | Completed |
| Pamrevlumab (FG-3019) | Pancreatic Cancer Non-resectable | Phase 3 · NCT03941093 | Completed |
| Iron | Anemia | Phase 3 · NCT02278341 | Completed |
| Sub-Study: Pirfenidone | Idiopathic Pulmonary Fibrosis | Phase 2 · NCT01890265 | Completed |
| Nab-paclitaxel | Pancreatic Cancer (Unresectable) | Phase 1/2 · NCT02210559 | Completed |
| IV Iron | Dialysis | Phase 2 · NCT01414075 | Completed |
| Anti-CD46 Antibody-drug Conjugate FOR46 | Metastatic Castration-resistant Prostate Cancer | Phase 1/2 · NCT05011188 | Active not recruiting |
| ASP1517 | Healthy Subjects | Phase 1 · NCT02952040 | Completed |
| Zirconium Zr 89-DFO-YS5 | Bladder Cancer | Phase 1 · NCT07664397 | Recruiting |
Also used in these trials (approved or third-party drugs, not KYNB's own candidates): Darbepoetin Alfa, Epoetin Alfa, Nintedanib, Pegfilgrastim, Gemcitabine Hydrochloride, Enzalutamide, Lanthanum Carbonate.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
KYNB had $95.3M in cash and short-term investments on its Jun 30, 2026 balance sheet. Including the cash events since then, it holds about $53.1M pro forma, before operating spending after that date:
It burns about $8.9M/quarter from operations, an estimated runway of 17.8 months from Jun 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Based on our current operating plans, we expect that our cash, cash equivalents, investments and accounts receivable will be sufficient to fund our operations into 2028; however, we may exhaust our capital resources sooner than expected and may need additional funding earlier than planned.10-Q, Nov 2026
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when KYNB files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Armistice Capital, LLC | Institution (13G, 5%+) | 400,000 | 9.88% | 2026-09-30 |
| Christine Chung SVP, CHINA OPERATIONS |
Insider | 294,903 | 7.28% | 2025-03-06 |
| Juan Graham CHIEF FINANCIAL OFFICER |
Insider | 164,863 | 4.07% | 2024-12-06 |
| James A Schoeneck Director · +127,000 options |
Insider | 39,666 | 0.98% | 2025-06-30 |
| Thane Wettig CEO, Director · +1.36M options |
Insider | 26,836 | 0.66% | 2026-09-06 |
| David DeLucia Chief Financial Officer · +551,000 options |
Insider | 4,355 | 0.11% | 2026-09-06 |
Share count 4,049,985 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for KYNB and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →